Nivolumab

Common brands: Opdivo, Yervoy, Cabometyx, Carboplatin, Kyxata

Top reporter: E.R. Squibb & Sons, L.L.C.

Programmed Death Receptor-1 Blocking Antibody [EPC]CTLA-4-directed Blocking Antibody [EPC]Platinum-based Drug [EPC]Corticosteroid [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]
94,349
Total Reports
55,197
Serious Reports
24,314
Death Reports
30
Reported Reactions
Death Report Ratio: High (25.77%)

Patient Demographics

Male
53,091
Female
28,294

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Nivolumab.

# Reaction Reports % of Total
1 DEATH 11,723
13.2%
2 MALIGNANT NEOPLASM PROGRESSION 9,728
10.9%
3 OFF LABEL USE 6,131
6.9%
4 DIARRHOEA 5,151
5.8%
5 FATIGUE 4,111
4.6%
6 PYREXIA 3,660
4.1%
7 INTENTIONAL PRODUCT USE ISSUE 3,331
3.7%
8 NAUSEA 3,130
3.5%
9 RASH 3,027
3.4%
10 DECREASED APPETITE 2,866
3.2%
11 DYSPNOEA 2,647
3.0%
12 PNEUMONIA 2,422
2.7%
13 COLITIS 2,220
2.5%
14 PNEUMONITIS 2,152
2.4%
15 ASTHENIA 2,069
2.3%
16 HYPOTHYROIDISM 2,060
2.3%
17 VOMITING 2,047
2.3%
18 ACUTE KIDNEY INJURY 1,858
2.1%
19 WEIGHT DECREASED 1,819
2.0%
20 PRURITUS 1,748
2.0%
21 ANAEMIA 1,740
2.0%
22 DRUG INEFFECTIVE 1,727
1.9%
23 INTERSTITIAL LUNG DISEASE 1,614
1.8%
24 GENERAL PHYSICAL HEALTH DETERIORATION 1,571
1.8%
25 MALAISE 1,522
1.7%
26 ARTHRALGIA 1,487
1.7%
27 IMMUNE-MEDIATED ENTEROCOLITIS 1,395
1.6%
28 CONSTIPATION 1,372
1.5%
29 ADRENAL INSUFFICIENCY 1,356
1.5%
30 PRODUCT USE IN UNAPPROVED INDICATION 1,347
1.5%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.